Capital World Investors Has $16.61 Million Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Capital World Investors boosted its holdings in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 64.3% during the third quarter, HoldingsChannel.com reports. The fund owned 684,805 shares of the company’s stock after purchasing an additional 267,982 shares during the period. Capital World Investors’ holdings in Centessa Pharmaceuticals were worth $16,607,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. lifted its stake in Centessa Pharmaceuticals by 20.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after purchasing an additional 1,449,000 shares during the period. Commodore Capital LP boosted its holdings in Centessa Pharmaceuticals by 39.3% during the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock valued at $43,340,000 after purchasing an additional 930,711 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $42,429,000. Stempoint Capital LP raised its holdings in shares of Centessa Pharmaceuticals by 113.3% in the 2nd quarter. Stempoint Capital LP now owns 1,265,672 shares of the company’s stock worth $16,631,000 after buying an additional 672,337 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter worth approximately $16,052,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Wolfe Research assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $40.00 target price on the stock. Truist Financial upped their target price on shares of Centessa Pharmaceuticals from $33.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, B. Riley Financial increased their target price on shares of Centessa Pharmaceuticals from $33.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $39.80.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Iqbal J. Hussain sold 38,951 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares of the company’s stock, valued at approximately $1,449,771.75. This represents a 40.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.09% of the stock is owned by company insiders.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock opened at $27.22 on Friday. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $9.60 and a 1 year high of $30.58. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The firm’s 50 day moving average is $24.64 and its 200-day moving average is $24.17. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of -14.87 and a beta of 1.55.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.